Regression of Cardiac Insufficiency After Ambulatory Intravenous Deferoxamine in Thalassemia Major
- 1 April 1993
- Vol. 103 (4) , 1276-1278
- https://doi.org/10.1378/chest.103.4.1276
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- In vivo platelet activation in beta-thalassemia major reflected by increased platelet-thromboxane urinary metabolitesBlood, 1991
- Chelation Therapy and Cardiac Status in Older Patients with Thalassemia MajorJournal of Pediatric Hematology/Oncology, 1990
- SURVIVAL AND CAUSES OF DEATH IN THALASSAEMIA MAJORPublished by Elsevier ,1989
- Visual and Auditory Neurotoxicity in Patients Receiving Subcutaneous Deferoxamine InfusionsNew England Journal of Medicine, 1986
- Prevention of Cardiac Disease by Subcutaneous Deferoxamine in Patients with Thalassemia MajorNew England Journal of Medicine, 1985
- Deferoxamine (Desferal®)-induced Toxic Retinal Pigmentary Degeneration and Presumed Optic NeuropathyOphthalmology, 1984
- Subclavian vein thrombosis in patients treated with infusion chemotherapy for advanced malignancyCancer, 1983
- Ferrioxamine excretion in iron-loaded manBlood, 1982
- LONGITUDINAL STUDY OF CARDIAC FUNCTION IN THALASSEMIA MAJOR *Annals of the New York Academy of Sciences, 1980
- Iron chelation therapy with deferoxamine in Cooley anemiaThe Journal of Pediatrics, 1978